Trastuzumab-resistant, ErbB-2-positive BT474 breast cancer cells were generated by treating cells with 10 μg ml−1 trastuzumab for 6 months in vitro as described previously (Osipo et al, 2008). This evidence concerns the gene ERBB2 and breast cancer.